The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Summary The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

Saved in:
Bibliographic Details
Published inJournal of dermatological science Vol. 50; no. 3; pp. 232 - 235
Main Authors Sredni-Kenigsbuch, Dvora, Shohat, Michael, Shohat, Batia, Ben-Amitai, Dan, Chan, Chi-Chao, David, Michael
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ireland Ltd 01.06.2008
Subjects
Adjuvants, Immunologic - pharmacology
Child
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - immunology
Dermatology
Ethylenes - pharmacology
Humans
In Vitro Techniques
Interleukin-10 - metabolism
p38 Mitogen-Activated Protein Kinases - metabolism
Online AccessGet full text

Cover

More Information
Summary:Summary The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0923-1811
1873-569X
DOI:10.1016/j.jdermsci.2007.12.007